Bayer takes another swipe at Nexavar compulsory licence
15-10-2013
A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Nexavar, Bayer, Mumbai High Court, India, Compulsory Licence,
